QALY Episodes
Oct. 19, 2023
Biosimilars' Slow Uptake
Wayne Winegarden, Senior Fellow at the Pacific Research Institute, discusses the news that AbbVie still controls more than 97 percent of the market nearly a year after Humira biosimilars launched; Darius Lakdawalla, Co-Autho…
None
Oct. 5, 2023
ICER’s Faux Updates
John O’Brien, President and CEO of the National Pharmaceutical Council, weighs in on ICER’s latest update that we are calling a “faux update”; The American Enterprise Institute has released its perspective on last year’s Inf…
None
Sept. 28, 2023
QALY Update
Bill Smith, Director of the Life Sciences Initiative at the Pioneer Institute, dives into the so-called update to ICER’s value assessment framework; Congresswoman Cathy McMorris Rodgers explained earlier this year why she wa…
None
June 13, 2023
Patients on Capitol Hill
Michael Riotto, a patient advocate from PA-01, says the QALY is top of mind for him as he attends the 2023 Patients Rising Now ‘We The Patients’ Fly-In; Tomiyo Williams, a patient advocate from GA-6, shares how step therapy …
None
April 25, 2023
PBM Lawsuit; How QALYs Discriminate
A new book from Dr. Bill Smith of the Pioneer Institute outlines how quality-adjusted life-years (QALYs) discriminate against patients and threaten rare disease innovation; Antonio Ciaccia breaks down Ohio’s lawsuit against …
None
April 6, 2023
Discriminatory Health Metrics, Inclusive VA Healthcare
Neal Masia, Health Economist and Columbia University Professor of Business and Economics, discusses how the QALY discriminates against rare and chronic disease patients and calls for a more patient-focused health technology …
None